GlassScriptPhysician profile
Tamara Ann Coleman
NPI 1639729759
$7,123.45
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $4,164 · 2023: $1,995 · 2024: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Long Term Medical Supply Or Device Loan: $299 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.55 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $884.76 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $388.09 | 2021-2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $385.07 | 2022-2023 | Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $378.24 | 2021-2023 | Calquence, Tagrisso, Imfinzi |
| Genentech USA, INC. | $354.95 | 2021-2023 | Gavreto, Tecentriq, Alecensa |
| Astellas Pharma US INC | $309.64 | 2021-2024 | Veozah, Xospata |
| Celgene Corporation | $249.30 | 2021-2023 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $242.58 | 2021-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $227.71 | 2021-2023 | Imbruvica |
| Daiichi Sankyo INC. | $211.53 | 2021-2022 | |
| Eisai INC. | $208.74 | 2021-2023 | |
| Incyte Corporation | $204.81 | 2021-2023 | Monjuvi, Pemazyre, Jakafi |
| Seagen INC. | $200.24 | 2022-2023 | Tukysa, Padcev |
| Genzyme Corporation | $194.17 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $191.13 | 2022-2023 | Libtayo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.